{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T12:58:05Z","timestamp":1774270685574,"version":"3.50.1"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,23]]},"DOI":"10.7759\/cureus.105695","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T12:09:28Z","timestamp":1774267768000},"source":"Crossref","is-referenced-by-count":0,"title":["Role of FMS-Like Tyrosine Kinase 3 (FLT3) Inhibitors in a Patient With T\/Myeloid Acute Leukemia With an FLT3 Mutation"],"prefix":"10.7759","author":[{"given":"Nicholas","family":"Elias","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahsun","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talal","family":"Bazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Lebovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106539","article-title":"Hybrid chemotherapy regimen (FLAG-IDA-vincristine-prednisone) for acute leukemia with mixed-phenotype blasts","volume":"103","author":"Reid JH","year":"2021","unstructured":"Reid JH, Perissinotti AJ, Benitez LL, et al.. Hybrid chemotherapy regimen (FLAG-IDA-vincristine-prednisone) for acute leukemia with mixed-phenotype blasts. Leuk Res. 2021, 103:106539. 10.1016\/j.leukres.2021.106539","journal-title":"Leuk Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13717","article-title":"Use of midostaurin in mixed phenotype acute leukemia with FLT3 mutation: a case series","volume":"108","author":"Tremblay Z","year":"2022","unstructured":"Tremblay Z, Wong A, Otis AS, et al.. Use of midostaurin in mixed phenotype acute leukemia with FLT3 mutation: a case series. Eur J Haematol. 2022, 108:163-5. 10.1111\/ejh.13717","journal-title":"Eur J Haematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10081974","article-title":"Mixed-phenotype acute leukemia: clinical diagnosis and therapeutic strategies","volume":"10","author":"George BS","year":"2022","unstructured":"George BS, Yohannan B, Gonzalez A, Rios A. Mixed-phenotype acute leukemia: clinical diagnosis and therapeutic strategies. Biomedicines. 2022, 10:1974. 10.3390\/biomedicines10081974","journal-title":"Biomedicines"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.202","article-title":"Mixed-phenotype acute leukemia: historical overview and a new definition","volume":"24","author":"Weinberg OK","year":"2010","unstructured":"Weinberg OK, Arber DA. Mixed-phenotype acute leukemia: historical overview and a new definition. Leukemia. 2010, 24:1844-51. 10.1038\/leu.2010.202","journal-title":"Leukemia"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi H","year":"2020","unstructured":"Kiyoi H, Kawashima N, Ishikawa Y. FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development. Cancer Sci. 2020, 111:312-22. 10.1111\/cas.14274","journal-title":"Cancer Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone RM","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, et al.. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017, 377:454-64. 10.1056\/NEJMoa1614359","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/376925-role-of-fms-like-tyrosine-kinase-3-flt3-inhibitors-in-a-patient-with-tmyeloid-acute-leukemia-with-an-flt3-mutation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T12:09:29Z","timestamp":1774267769000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/376925-role-of-fms-like-tyrosine-kinase-3-flt3-inhibitors-in-a-patient-with-tmyeloid-acute-leukemia-with-an-flt3-mutation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":6,"URL":"https:\/\/doi.org\/10.7759\/cureus.105695","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,23]]}}}